LawPlayer
My bookmarksSign up freeSign up free
Source

Commission Implementing Decision (EU) 2017/2201 of 27 November 2017 authorising the placing on the market of 2′-fucosyllactose produced with Escherichia coli strain BL21 as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document C(2017) 7662)

Commission Implementing Decision (EU) 2017/2201 of 27 November 2017 authorising the placing on the market of 2′-fucosyllactose produced with Escherichia coli strain BL21 as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document C(2017) 7662)

Implementing Decision (EU) 2017/2201 · Decision · 5 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

Without prejudice to Regulation (EU) No 609/2013, 2′-fucosyllactose powder and liquid concentrate as specified in Annex I to this Decision may be placed on the Union market as a novel food ingredient for the uses defined and at the maximum level established in Annex II to this Decision.

Article 2

Open ↗

The designation of 2′-fucosyllactose powder and liquid concentrate authorised by this Decision on the labelling of the foodstuffs shall be ‘2′-fucosyllactose’ for the powder and for the liquid concentrate.

Article 3

Open ↗

This Decision is addressed to Jennewein Biotechnologie GmbH, Maarweg 32, 53619 Rheinbreitbach, Germany.

Supplementary provisions

ANNEX ISupplementary provisions

Open ↗

ANNEX I SPECIFICATIONS OF 2′-FUCOSYLLACTOSE Definition: Chemical name α-L-fucopyranosyl-(1→2)-β-D-galactopyranosyl-(1→4)-D-glucopyranoside Chemical formula C 18 H 32 O 15 Molecular mass 488,44 Da CAS No. 41263-94-9 Description: 2′-fucosyllactose powder produced with a genetically modified strain of Escherichia coli BL21 is a white to ivory powder that is derived from 2′-fucosyllactose liquid concentrate by spray drying. The 2′-fucosyllactose liquid concentrate is a colourless to slight yellow clear 45 % w/v ± 5 % w/v aqueous solution. Specifications of 2′-fucosyllactose powder Specification Parameter Limits Physical parameter White to ivory colour   Chemical analysis 2′-fucosyllactose ≥ 90 % Lactose ≤ 5 % 3-fucosyllactose ≤ 5 % Difucosyllactose ≤ 5 % Fucosylgalactose ≤ 3 % Glucose ≤ 3 % Galactose ≤ 3 % Fucose ≤ 3 % GMO detection Negative   Water content   ≤ 9,0 % Protein content   ≤ 100 μg/g Total Ash   ≤ 0,5 % Contaminants Lead ≤ 0,02 mg/kg Arsenic ≤ 0,2 mg/kg Cadmium ≤ 0,1 mg/kg Mercury ≤ 0,5 mg/kg Aflatoxin M 1 ≤ 0,025 μg/kg Microbial Parameters Total Plate Count (TPC) ≤ 10 4 CFU/g Enterobacteria /Coliforms absent in 11 g Yeast and Mould ≤ 100 CFU/g Salmonella spp. Negative/100 g Cronobacter spp. Negative/100 g Endotoxins ≤ 100 EU/g CFU: Colony Forming Units; EU: Endotoxin Units Specifications of 2′-fucosyllactose liquid concentrate Specification Parameter Limits Physical parameter Colourless to slightly yellow, clear solution   Solids content   45 % w/v (+/– 5 % w/v) dry matter in water Chemical analysis 2′-fucosyllactose ≥ 90 % Lactose ≤ 5 % 3-fucosyllactose ≤ 5 % Difucosyllactose ≤ 5 % Fucosylgalactose ≤ 3 % Glucose ≤ 3 % Galactose ≤ 3 % Fucose ≤ 3 % GMO detection Negative   Protein content   ≤ 100 μg/g Total Ash   ≤ 0,5 % Contaminants Lead ≤ 0,02 mg/kg Arsenic ≤ 0,2 mg/kg Cadmium ≤ 0,1 mg/kg Mercury ≤ 0,5 mg/kg Aflatoxin M 1 ≤ 0,025 μg/kg Microbial Parameters Total Plate Count (TPC) ≤ 5 000 CFU/g Enterobacteria /Coliforms absent in 11 g Yeast and Mould ≤ 50 CFU/g Salmonella spp. Negative/200 ml Cronobacter spp. Negative/200 ml Endotoxins ≤ 100 EU/ml CFU: Colony Forming Units; EU: Endotoxin Units

ANNEX IISupplementary provisions

Open ↗

ANNEX II Authorised uses of 2′-fucosyllactose powder and liquid concentrate Food category Maximum level Infant formulae and follow-on formulae 1,2 gram 2′-fucosyllactose per litre final product ready for use marketed as such or reconstituted as instructed by the manufacturer.

Other acts of the same type
2011/797/EU: Commission Implementing Decision of 30 November 2011 establishing the financial contribution by the Union to the expenditure incurred in the context of the emergency measures taken to combat Newcastle disease in Spain in 2009 (notified under document C(2011) 8717)2011/798/EU: Commission Implementing Decision of 30 November 2011 on a financial contribution from the Union towards emergency measures to combat avian influenza in Spain in 2009 (notified under document C(2011) 8721)2011/799/EU: Commission Implementing Decision of 30 November 2011 on a financial contribution from the Union towards emergency measures to combat avian influenza in Poland in 2007 (notified under document C(2011) 8722)2011/800/EU: Commission Implementing Decision of 30 November 2011 on a financial contribution from the Union towards emergency measures to combat bluetongue in Germany in 2007 (notified under document C(2011) 8723)2011/801/EU: Commission Implementing Decision of 30 November 2011 establishing the financial contribution by the Union to the expenditure incurred in the context of the emergency vaccination plans against bluetongue in France in 2007 and 2008 (notified under document C(2011) 8727)2011/802/EU: Commission Implementing Decision of 30 November 2011 establishing the financial contribution by the Union to the expenditure incurred in the context of the emergency vaccination plans against bluetongue in Italy in 2007 and 2008 (notified under document C(2011) 8728)2011/803/EU: Commission Implementing Decision of 30 November 2011 establishing the financial contribution by the Union to the expenditure incurred in the context of the emergency vaccination plans against bluetongue in Austria in 2007 and 2008 (notified under document C(2011) 8729)2011/804/EU: Commission Implementing Decision of 30 November 2011 establishing the financial contribution by the Union to the expenditure incurred in the context of the emergency vaccination plans against bluetongue in the Netherlands in 2007 and 2008 (notified under document C(2011) 8732)2011/805/EU: Commission Implementing Decision of 30 November 2011 establishing the financial contribution by the Union to the expenditure incurred in the context of the emergency vaccination plans against bluetongue in Sweden in 2007 and 2008 (notified under document C(2011) 8737)2011/806/EU: Commission Implementing Decision of 30 November 2011 establishing the financial contribution by the Union to the expenditure incurred in the context of the emergency vaccination plans against bluetongue in Luxembourg in 2007 and 2008 (notified under document C(2011) 8742)2011/807/EU: Commission Implementing Decision of 30 November 2011 approving annual and multiannual programmes and the financial contribution from the Union for the eradication, control and monitoring of certain animal diseases and zoonoses presented by the Member States for 2012 and following years (notified under document C(2011) 8719)2011/809/EU: Council Decision of 30 November 2011 on the position to be taken by the European Union within the General Council of the World Trade Organization on the extension of the WTO waiver in order to implement the EU autonomous preferential trade regime for the Western Balkans

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next